Monogram Orthopaedics Inc

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Monogram Orthopaedics Inc (MGRM) reports strong Q3 performance and eyes international growth

Monogram Orthopaedics Inc (MGRM) shows strong financial performance with strategic milestones achieved and regulatory progress.
Challenges include high marketing expenses impacting burn rate and the need to focus on international markets for revenue generation.
Opportunities lie in FDA clearance anticipation, market dynamics favoring robotic surgery adoption, and consumables revenue potential post-clearance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Monogram Technologies, Inc. operates as a medical technology company. It intends to produce and market robotic surgical equipment and related software, orthopaedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. The company was founded by Douglas Unis in 2015 and is headquartered in Austin, TX.

Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request Management Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.

Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open market by certain related parties including Chief Financial Officer Noel Knape, totaling approximately $1 million. Additional details can be found on the Form 8-K filed today by the Company under Item 8.01 Other Events.

Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million

Monogram Technologies Inc. (NASDAQ:MGRM ) Q3 2024 Earnings Call Transcript November 19, 2024 4:30 PM ET Company Participants Ben Sexson - CEO Noel Knape - CFO Larry Holub - IR Conference Call Participants Tom Kerr - Zacks Investment Research Operator Greetings and welcome to the Monogram Technologies Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Monogram Technologies Inc. (MGRM) Q3 2024 Earnings Call Transcript

Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones Management to Host Business Update Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / November 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the third quarter ended September 30, 2024.

Monogram Technologies Reports Third Quarter 2024 Financial Results

AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones.

Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

Award from Medical Tech Outlook Highlights Monogram's mBôs TKA System AUSTIN, TX / ACCESSWIRE / October 29, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has been named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook. Monogram Technologies mBôs TKA Precision Robotic Surgical System This award is in recognition of Monogram's stellar reputation and trust among customers and industry peers, evident in the numerous nominations received from Medical Tech Outlook's subscribers.

Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024

AUSTIN, TX / ACCESSWIRE / October 16, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will attend the LD Micro Main Event XVII Conference being held at the Luxe Sunset Blvd Hotel in Los Angeles, CA October 29 - 30, 2024. Monogram Chief Financial Officer Noel Knape will conduct in-person one-on-one meetings during the conference to discuss the Company's novel mBôs precision robotic surgical system.

Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024

Company Has 180 Days From Receipt to Produce Additional Information AUSTIN, TX / ACCESSWIRE / October 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced a correction to its press release issued on Wednesday, October 2, 2024, entitled "Monogram Technologies Receives FDA Response for mBôs TKA System" (the "Prior Press Release"). In yesterday's prior press release, dated October 2, 2024, it was stated in the subtitle that: "Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days.

CORRECTION FROM SOURCE: Monogram Technologies Issues Correction to Press Release Announcing it Received an FDA Response for its mBôs TKA System

Company to Conduct Clinical Trial to Produce Additional Information Within 180 Days AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has received an Additional Information Request ("AIR") from the U.S. Food and Drug Administration ("FDA") on September 30, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.

Monogram Technologies Receives FDA Response for mBôs TKA System

AUSTIN, TX / ACCESSWIRE / October 2, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today that the Company closed the previously announced 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") continuous offering on October 1, 2024. The Company sold 5,790,479 units, with each unit consisting of (a) one share of the Company's Series D Preferred Stock and (b) one common stock purchase warrant to purchase one share of the Company's common stock, $0.001 par value per share (the "Common Stock"), for a total of 5,790,479 shares of the Company's Series D Preferred Stock and warrants to purchase an aggregate of 5,790,479 shares of the Company's Common Stock (and shares of Common Stock underlying shares of Series D Preferred Stock, PIK dividends on Series D Preferred Stock, and all such warrants).

Monogram Technologies Announces Closing of Upsized and Oversubscribed $13 Million Public Offering

AUSTIN, TX / ACCESSWIRE / October 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced today the declaration of a dividend of $0.0255 per share payable to holders of record of shares of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") at the close of business on October 1, 2024. In addition, the Company announced that it will be paying the dividend in kind based on the closing price of its common stock, par value $0.001 per share on September 30, 2024.

Monogram Technologies Announces Preferred Stock Dividends

AUSTIN, TX / ACCESSWIRE / September 11, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced an upsize of its previously announced continuous offering of units from $10 million to $12.5 million of units. Each unit consists of (a) one share of the Company's 8.00% Series D Convertible Cumulative Preferred Stock (the "Series D Preferred Stock") and (b) one common stock purchase warrant to purchase one share of its common stock, $0.001 par value per share (the "Common Stock").

Monogram Technologies Upsizes 8.00% Series D Convertible Cumulative Preferred Stock and Warrant Offering to $12.5 Million

Monogram Technologies Inc. (MGRM) Q2 2024 Earnings Call Transcript

Submitted FDA 510(k) Application and Passed FDA Administrative Review for the mBôs TKA System Secured Initial Strategic Multicenter Clinical Trial Collaboration with Shalby Limited Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / August 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the second quarter ended June 30, 2024.

Monogram Technologies Reports Second Quarter 2024 Financial Results

Clinical Trial Collaboration Follows 510(k) Submission and Passing of FDA Administrative Review; Preludes Planned International Launch for the mBȏs TKA System Strategic Partner Shalby is Recognized as one of the Leading Institutions for Orthopedic Surgeries Worldwide, Performing Over 14,000 Annual Knee Replacement Surgeries Globally AUSTIN, TX / ACCESSWIRE / August 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced its strategic collaboration with Shalby Limited (NSE:SHALBY) ("Shalby"), a global muti-specialty hospital chain and one of India's leading orthopedic hospital groups, to conduct a multicenter clinical trial to demonstrate the safety and effectiveness of the mBȏs TKA System.Shalby is the largest (ranked #1 in arthroplasty by volume) orthopedic hospital chain in the world employing over 4,000 people at 14 hospitals in 13 cities and more than 3 million patients treated. Shalby represents approximately 15% of the organized arthroplasty market in India, which has an approximate market size of 200,000 TKAs per year (with a compound annual growth rate of approximately 20% and a population of 1.4 billion people).

Monogram Technologies Secures Initial Strategic Clinical Trial Collaboration

Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for the Company's mBôs TKA System. The application was submitted on July 19, 2024, and passed the FDA Administrative Review.

Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance

AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a business update conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the second quarter ended June 30, 2024 and to discuss key milestones.

Monogram Technologies to Host Second Quarter 2024 Business Update Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time

Management to Showcase Product Demonstration of mBôs Precision Robotic Surgical System and mVision Technologies AUSTIN, TX / ACCESSWIRE / June 3, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will host an investor and analyst day on Thursday, June 20th, 2024, from 9:00 a.m. CDT to 1:00 p.m.

Monogram Technologies to Host Investor and Analyst Tour at its Headquarters in Austin, Texas, on Thursday, June 20th, 2024

Monogram Technologies Inc. (NASDAQ:MGRM ) Q1 2024 Earnings Conference Call May 22, 2024 4:30 PM ET Company Participants Larry Holub - Investor Relations, MZ Group North America Noel Knape - Chief Financial Officer Ben Sexson - Chief Executive Officer Larry Holub Welcome to the Monogram Technologies First Quarter 2024 Business Update Conference Call. I'm Larry Holub, Director at MZ Group North America, representing Monogram Technologies as their external Investor Relations Adviser.

Monogram Technologies Inc. (MGRM) Q1 2024 Earnings Call Transcript

New Name Reflects Continued Evolution as an AI-Driven Robotics Company with a Strong IP Position AUSTIN, TX / ACCESSWIRE / May 15, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced its plan to merge its wholly owned subsidiary, Monogram Technologies Inc. ("MT") with and into Monogram Orthopaedics Inc. In connection with this upstream merger, the current MT will cease to exist, and Monogram's business will continue as it is currently being conducted. Further, on May 15, 2024, the effective date of the merger, the Company will change its name to Monogram Technologies Inc., and its ticker will remain "MGRM.

Monogram Orthopaedics Completes Corporate Name Change to Monogram Technologies

Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half of 2024 Engaged Contract Research Organization to Oversee mBôs Robot Clinical Trial Activities Outside the U.S. Management to Host Business Update Conference Call on Wednesday, May 22 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / May 14, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2024.

Monogram Orthopaedics Reports First Quarter 2024 Financial Results

CRO Expands Clinical Capabilities, Accelerating Product Pipeline Development and Commercialization Opportunities AUSTIN, TX / ACCESSWIRE / May 13, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced it has engaged a global Contract Research Organization (CRO) to oversee its clinical trial activities for its mBôs Total Knee Arthroplasty (TKA) System and represent its submission to the local regulators outside the United States. The transnational CRO, which the Company cannot disclose due to competitive reasons, has extensive experience and successful FDA submissions from clinical investigations conducted Outside the United States (OUS).

Monogram Engages Contract Research Organization to Oversee mBôs Robot Clinical Trial Activities Outside the U.S.

510(k) Submission with FDA Accelerated for Early Second Half of 2024 AUSTIN, TX / ACCESSWIRE / May 1, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update related to the regulatory and commercialization path for its mBôs surgical system following its meeting with the U.S. Food and Drug Administration (the "FDA"). On April 19, 2024, Monogram received written feedback from the FDA regarding the Company's Q1 2023 pre-submission request.

Monogram Provides Regulatory Update Following Meeting with FDA

Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs System AUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA. NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures with go-to-market support, expertise, and technology assistance.

Monogram Accepted to NVIDIA Inception Program

Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript

News for Monogram Orthopaedics Inc Stock (MGRM)